1. United States Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
BioScience Health Innovations Inc

BioScience Health Innovations Inc

OOTC:BHIC
5.50
USD
-0.29
(-5.02%)
-0.02EPS
46.46MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.06
0.07
0.18
0.52
0.45
Basic EPS, GAAP
- -
-0.01
-0.02
-0.06
-0.14
-0.03
0.01
0.06
-0.02
Free Cash Flow per Basic Share
- -
-0.01
-0.02
-0.06
-0.15
-0.04
- -
0.01
-0.09
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.01
-0.01
0.01
-0.01
- -
0.08
0.13
0.16
Tangible Book Value per Share
- -
0.01
-0.01
0.01
-0.01
- -
0.07
0.13
0.15
Basic Weighted Avg Shares
3
1
1
1
1
8
10
11
11
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
2
6
5
Operating Margin (%)
- -
- -
- -
- -
-245.81
-42.09
4.72
12.64
-2.87
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
10.7
- -
Profit Margin (%)
- -
- -
- -
- -
-245.81
-42.09
4.72
11.29
-3.74
Working Capital
- -
- -
- -
- -
- -
- -
1
1
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
1
1
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
21
53.7
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
21
55.53
- -
Return on Common Equity (%)
- -
-104.39
- -
- -
- -
- -
- -
55.53
-12.37

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
- -
24
46

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2
2
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
1
1
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2,574.26%
76.87%
Free Cash Flow
- -
-774.84%
-4,148.02%
Net Income, GAAP
- -
176.15%
638.03%
Sales/Revenue/Turnover
- -
- -
208.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
1
1
2
2025
1
2
- -
2
6
2026
1
1
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.01
0.01
- -
0.01
2025
0.04
0.04
- -
-0.02
0.06
2026
-0.02
-0.02
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Darren J. Lopez
Sector
Retail trade
Industry
Drugstore chains
Address
Bluffdale United States
CIK
0001784440
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
TSURUHA Holdings, Inc. (TSE:3391)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
BioScience Health Innovations Inc. is a biotechnology and healthcare solutions enterprise engaged in the research, development, commercialization, and distribution of advanced therapeutic products, wellness formulations, and health management technologies. The company operates across three primary business segments: Bioceutical & Nutritional Therapeutics, Preventative Diagnostics, and Digital Health Platforms. Its core product and service portfolio comprises proprietary dietary and bioactive nutritional supplements targeting metabolic, cellular, and immune health; therapeutic botanical compounds and preventative formulations; point-of-care and direct-to-consumer diagnostic screening kits; preventative biomedical monitoring devices; and digital telehealth consultation and remote patient management services tailored for chronic wellness and outpatient care. BioScience Health Innovations Inc. distributes its offerings to retail pharmacies, healthcare practitioners, wellness clinics, medical institutions, and direct consumers primarily throughout North America, with selective distribution partnerships in international markets. In recent strategic and operational developments, the company has expanded its market footprint and product pipeline through key commercial alliances, securing strategic co-distribution agreements with regional healthcare distributors and entering into collaborative licensing arrangements for proprietary botanical formulations. The company recently completed a targeted financing round to fund the clinical validation and commercial scale-up of its next-generation wellness line, launched an integrated e-commerce and telehealth patient-care platform, and acquired intellectual property assets in bioceutical extraction technology. In addition, BioScience Health Innovations Inc. implemented a corporate reorganization to optimize its supply chain logistics, streamline regulatory compliance procedures, and consolidate laboratory research operations. Founded in 2018, BioScience Health Innovations Inc. is headquartered in the United States.